Impact of Staphylococcus aureus bacteremia in COVID-19 patients

Abstract

Introduction. The disease caused by SARS-CoV-2 (COVID-19) has been a challenge for healthcare professionals since its appearance. Staphylococcus aureus has been described as one of the main pathogens causing bacterial infections in viral pandemics. However, co- infection with S. aureus causing bacteremia in patients with COVID-19 has yet to be well studied. Methods. We performed a e study of S. aureus bacteremia (SAB) at Hospital Miguel Servet (Zaragoza) from March 2020 to February 2021. The clinical characteristics, mortality and risk factors of adults hospitalized patients with BSA associated COVID-19 compared to patients without COVID-19. Results. A total of 95 patients with SAB were identified. 27.3% were positive for SARS-CoV-2. SAB represented 9.9% of bacteremia, being the second agent in frequency after E. coli. Nosocomial bacteremia was more frequent in the group of COVID-19 patients. The most frequent source of BSA in these patients was the respiratory source (26.9% vs 0%; P<0.001) followed by the skin (15.5% vs 15.9%; P=1). The development of sepsis was more frequent in COVID-19 patients (61,5% vs 7,8%; P=0,336) and among them, who received dexamethasone at doses > 6 mg/day (62.5% vs. 37.5%, P<0.05). Conclusions. Our data suggest that BSA has a negative impact on the evolution of patients with COVID-19. However, further and preferably prospective studies are required to obtain solid data on the impact of BSA on coronavirus patients.

Post-COVID-19 Spondylodiscitis: A Case Study and Review of the Literature

“…Persistent or recurrent staphylococcal bacteriaemia related to SD in the COVID-19 pandemic has been reported in other cases of young healthy patients and unapparent infectious foci, speculated to be accounted to the immune disfunction, with secondary (reactive) hemophagocytic lymphohistiocytosis and to the diffuse vascular damages [ 32 , 33 , 34 , 35 ]. The first line of anti-staphylococcal antibiotics aimed highly antibiotic resistant MRSA but resulted in incompletely recovery after six weeks.…”

Prevalence and resistance trends of Gram positive cocci Staphylococcus aereus and Enterococcus spp. in a tertiary care hospital

“…In the recent COVID-19 Pandemic, it was reported that when the patients infected with SARS-CoV-2 were co-infected with S. aureus, especially when exposed to mechanical ventilation and/or receiving steroid therapy, the risk of mortality increased, and even the 30-day mortality was 67% 26,27 . Local epidemiological studies are needed in this regard.…”

ESKAPE and Beyond: The Burden of Coinfections in the COVID-19 Pandemic

“…Several epidemiological studies are currently being conducted in patients with COVID-19 who also suffer from a bacterial infection, specifically bacteraemia. An increasing incidence of coinfections in patients admitted to the ICU and an increased rate of infection with nosocomial MDR bacteria have been observed, creating the need for special care in the treatment of patients with COVID-19 [ 123 ].…”

“…The most frequent source of bacteraemia caused by S. aureus was respiratory (26.9%) followed by cutaneous (15.5%). Concluding that bacteraemia caused by this pathogen negatively influences the outcome of patients with COVID-19, suggesting that further studies are needed to obtain robust data on the impact of bacteraemias caused by S. aureus in patients infected with SARS-CoV-2 [ 123 ].…”